Highlights T2 Biosystems, Inc.

Equities

TTOO

US89853L3024

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
5.34 ^USD	-1.66%		-9.95%	-14.90%

06-25	T2 Biosystems Signs Exclusive Distribution Deal for Hong Kong, Macau	MT
06-25	T2 Biosystems Announces Commercial Expansion Through Hong Kong and Macau Distributor	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

T2 Biosystems Announces Commercial Expansion Through Hong Kong and Macau Distributor	06-25	CI
Sector Update: Health Care Stocks Advance Late Wednesday Afternoon	05-15	MT
Top Midday Gainers	05-15	MT
T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease	05-07	CI
T2 Biosystems, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Earnings Flash (TTOO) T2 BIOSYSTEMS Posts Q1 Revenue $2.1M	05-06	MT
T2 Biosystems, Inc. Reiterates Revenue Guidance for the Full Year 2024	05-06	CI
T2 Biosystems, Inc. Announces Commercial Expansion Through Middle East Distributor	05-06	CI
T2 Biosystems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc	03-28	CI
T2 Biosystems, Inc. Reiterates Revenue Guidance for the Year 2024	03-20	CI
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates	03-20	CI
T2 Biosystems, Inc. Announces Publication of New Study Highlighting Clinical Benefits and Performance of Real-World Use of T2Resistance Panel in Journal of Clinical Microbiology	03-18	CI
T2 Biosystems, Inc. Announces Commercial Expansion Through Distributors in Europe and Asia	02-15	CI
T2 Biosystems Gets 510(k) Clearance For Expanded T2Bacteria Panel	02-12	DJ
T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel	02-12	CI
T2 Biosystems Announces Participation in NIH-Funded Antibacterial Resistance Leadership Group Pilot Study for Pneumonia Patients	01-18	CI
T2 Biosystems, Inc. Announces FDA 510(K) Submission to Expand Use of the FDA-Cleared T2candida Panel to Include Pediatric Testing	01-03	CI
T2 Biosystems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-15	CI
T2 Biosystems, Inc. Highlights New Clinical Data Presented At IDWeek 2023 Conference	24/10/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights T2 Biosystems, Inc.

Equities

TTOO

US89853L3024

Highlights

Filters